NEW YORK, NY, Sept. 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has completed the funding of the Study Protocol phase of its recently initiated Clinical Trial. This purpose of which, is: to examine the Effects of Different Cannabidiol Doses on Reducing the Frequency and Severity of Nausea in Otherwise Healthy Pregnant Women with Excessive First Trimester Emesis and the Diagnosis of Hyperemesis Gravidarum. The finalized Study Protocol (“Protocol”) will be submitted to, reviewed by, and subject to approval from a central Institutional Review Board (“IRB”).
Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of its Recently Initiated Clinical Trial
